Primary Sjögren's syndrome

New England Journal of Medicine

Volumn 378, Issue 10, 2018, Pages 931-939

  Mariette, Xavier ^a   Criswell, Lindsey A ^b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C4; CREATININE; PILOCARPINE; RHEUMATOID FACTOR; RO ANTIBODY; ANALGESIC AGENT; ANTINUCLEAR ANTIBODY; IMMUNOLOGIC FACTOR; MUSCARINIC AGENT; RITUXIMAB;

ADULT; ARTICLE; CANCER RISK; CASE REPORT; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CRYOGLOBULINEMIA; DISEASE DURATION; DRY EYE; DYSPHAGIA; ECHOGRAPHY; EYE DISCOMFORT; FATIGUE; FEMALE; GAMMOPATHY; HAND PAIN; HUMAN; IMMUNOTHERAPY; JOINT SWELLING; LABORATORY TEST; LYMPHOCYTOPENIA; LYMPHOMA; MIDDLE AGED; PAROTID ENLARGEMENT; PHYSICAL EXAMINATION; POLYCLONAL GAMMOPATHY; PRIORITY JOURNAL; PURPURA; SJOEGREN SYNDROME; WRIST PAIN; XEROSTOMIA; BLOOD; COMPLICATION; DIAGNOSTIC IMAGING; PAROTID GLAND;

ANALGESICS; ANTIBODIES, ANTINUCLEAR; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; MUSCARINIC AGONISTS; PAROTID GLAND; RITUXIMAB; SJOGREN'S SYNDROME; ULTRASONOGRAPHY;

EID: 85043588525     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp1702514     Document Type: Article

References (37)

1. Qin B, Wang J, Yang Z, et al. Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 1983-9.
2. Meijer JM, Meiners PM, Huddleston Slater JJR, et al. Health-related quality of life, employment and disability in patients with Sjogren's syndrome. Rheumatology (Oxford) 2009; 48: 1077-82.
3. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and datadriven methodology involving three international patient cohorts. Ann Rheum Dis 2017; 76: 9-16.
4. Retamozo S, Brito-Zerón P, Zeher M, et al. Epidemiologic subsets drive a differentiated clinical and immunological presentation of primary Sjögren syndrome: Analysis of 9302 patients from the Big Data International Sjögren Cohort. Arthritis Rheumatol 2017; 69: Suppl 10; 876. abstract.
5. Fox RI. Sjögren's syndrome. Lancet 2005; 366: 321-31.
6. Jasiek M, Karras A, Le Guern V, et al. A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren's syndrome. Rheumatology (Oxford) 2017; 56: 362-70.
7. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci U S A 2006; 103: 2770-5.
8. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum 2005; 52: 1534-44.
9. Emamian ES, Leon JM, Lessard CJ, et al. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun 2009; 10: 285-96.
10. Hall JC, Casciola-Rosen L, Berger AE, et al. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A 2012; 109: 17609-14.
11. Rusakiewicz S, Nocturne G, Lazure T, et al. NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome. Sci Transl Med 2013; 5: 195ra96.
12. Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjögren's syndrome. Nat Rev Rheumatol 2013; 9: 544-56.
13. Lessard CJ, Li H, Adrianto I, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat Genet 2013; 45: 1284-92.
14. Li Y, Zhang K, Chen H, et al. A genomewide association study in Han Chinese identifies a susceptibility locus for primary Sjögren's syndrome at 7q11.23. Nat Genet 2013; 45: 1361-5.
15. Taylor KE, Wong Q, Levine DM, et al. Genome-wide association analysis reveals genetic heterogeneity of Sjögren's syndrome according to ancestry. Arthritis Rheumatol 2017; 69: 1294-305.
16. Mingueneau M, Boudaoud S, Haskett S, et al. Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren's signature correlating with disease activity and glandular inflammation. J Allergy Clin Immunol 2016; 137(6): 1809-1821.e12.
17. Tasaki S, Suzuki K, Nishikawa A, et al. Multiomic disease signatures converge to cytotoxic CD8 T cells in primary Sjögren's syndrome. Ann Rheum Dis 2017; 76: 1458-66.
18. Hammenfors DS, Brun JG, Jonsson R, Jonsson MV. Diagnostic utility of major salivary gland ultrasonography in primary Sjögren's syndrome. Clin Exp Rheumatol 2015; 33: 56-62.
19. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010; 69: 1103-9.
20. Seror R, Ravaud P, Mariette X, et al. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis 2011; 70: 968-72.
21. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165: 2337-44.
22. Nocturne G, Mariette X. Sjögren syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol 2015; 168: 317-27.
23. Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010; 304: 452-60.
24. Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. Arch Intern Med 1999; 159: 174-81.
25. Gottenberg JE, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 2014; 312: 249-58.
26. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 2004; 50: 1270-6.
27. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren's syndrome: a twelveweek randomized, double-blind, placebocontrolled pilot clinical trial. Arthritis Rheum 2004; 50: 2240-5.
28. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67: 1541-4.
29. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62: 960-8.
30. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 2014; 160: 233-42.
31. Bowman SJ, Everett CC, O'Dwyer JL, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren's syndrome. Arthritis Rheumatol 2017; 69: 1440-50.
32. Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the Auto Immune and Rituximab Registry. Ann Rheum Dis 2013; 72: 1026-31.
33. Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2015; 74: 526-31.
34. Vivino FB, Carsons SE, Foulks G, et al. New treatment guidelines for Sjögren's disease. Rheum Dis Clin North Am 2016; 42: 531-51.
35. Nocturne G, Cornec D, Seror R, Mariette X. New biological therapies in Sjögren's syndrome. Best Pract Res Clin Rheumatol 2015; 29: 783-93.
36. Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjögren syndrome. Nat Rev Rheumatol 2018 February 08 (Epub ahead of print).
37. Fisher B, Zeher M, Ng W, et al. The novel anti-CD40 monoclonal antibody CFZ533 shows beneficial effects in patients with primary Sjögren's syndrome: a phase IIa double-blind, placebo-controlled randomized trial. Arthritis Rheumatol 2017; 69: Suppl 10: 2538. abstract.